Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders

As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders” on 29 November 2025 in Kuala Lumpur, Malaysia.

A heartfelt thank you to all the healthcare professionals who joined us.
We were delighted to welcome nearly 200 participants, both onsite and online, including attendees from Indonesia, India, Taiwan, Singapore and Brunei.

Organised by Gene Solutions, and proudly supported by the Obstetrical and Gynaecological Society of Malaysia (OGSM) and the Malaysian Medical Association (MMA), the session brought together Consultant O&G and MFM specialists, a Clinical Geneticist & Consultant Paediatrician, and the Medical Director from Gene Solutions to share and discuss the latest advances in prenatal screening.

✨ Key Highlights from the Session

+ Beyond Aneuploidy — The evolution of NIPT through the integration of carrier screening and dominant single-gene disorder screening into NIPT.

+ Counselling as a Core Component — Clear communication drives informed decision-making.

+ Broader Clinical Value — Integrating recessive & dominant conditions for comprehensive prenatal insights.

+ Technology Enhancing Accuracy — NGS and AI-powered analytics enabling deeper, more reliable results.

Thank you for the strong regional support. We look forward to more collaborative learning ahead!

 

About Gene Solutions Malaysia

Established in 2023, Gene Solutions Malaysia is part of Gene Solutions, a global biotechnology company headquartered in Singapore and dedicated to making advanced genomic solutions more accessible and affordable.

We provide genomic testing and precision healthcare solutions across oncology, reproductive health and women’s health, leveraging Next-Generation Sequencing (NGS), multi-omics and Artificial Intelligence (AI).

The company offers a comprehensive portfolio across oncology, including early cancer screening (SPOT-MAS CRC, SPOT-MAS Lung), multi-cancer early detection (SPOT-MAS 10), and precision oncology (K-TRACK, K4CARE), as well as reproductive and women’s health solutions, including non-invasive prenatal testing (TriSure) and gynecologic cancer screening and triage (SPOT-MAS Eva, EpiHera).

Through collaborations with hospitals, healthcare institutions, laboratories and medical professionals across Malaysia, we are working to bring innovative genomic solutions into clinical practice and contribute to the advancement of precision medicine.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More